RxDoctor Payments Data

Heidi Pareja, MD

Family Medicine · Mission, TXNPI 1164861316

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 38 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$320
  • Amgen$223
  • Abbott$162
  • Novo Nordisk$134
  • Pfizer$53
  • Corcept Therapeutics$50
  • plus $193 from 8 others

What the payments were for

  • Food & beverage$1,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$39,541
Medicare patients
166
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$33,612
JardianceEmpagliflozin13$11,044
XareltoRivaroxaban14$10,163
Breo ElliptaFluticasone/Vilanterol14$5,689
Atorvastatin Calcium84$792
Celecoxib33$753
Losartan Potassium65$720
Gabapentin38$720
Levothyroxine Sodium59$715
SynthroidLevothyroxine Sodium16$690
Metoprolol Succinate49$423
Amlodipine Besylate67$377
Metformin Hcl63$377
Lisinopril64$339
Nifedipine ErNifedipine16$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$134$33,61233 claims
Johnson & JohnsonXarelto$12$10,16314 claims
GSKBreo Ellipta$48$5,68914 claims
AbbVieSynthroid$49$69016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →